Clinical Toxicology Regulatory Report Drafting
Draft CTD Module 2.3 safety narratives from toxicology data and adverse events
What You Can Do
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
Features
Consolidates adverse event data from parallel clinical trials into unified safety profiles with trend analysis
Transforms preclinical toxicology + limited human PK/PD into compliant 15-50 page safety sections
Year-over-year adverse event summaries with causality assessment and signal detection
Links receptor binding, metabolite data, and tissue distribution to clinical AE patterns
Rapid drafting of urgent safety communications for serious emerging signals
Structures vital signs, laboratory trends, and histopathology findings per CTD guidelines
Phase transition safety overviews (Phase 1→2, 2→3) with population-level risk stratification
Organizes clinical findings with mechanistic rationale for independent assessment committees
Example Output
Example 1: IND Safety Module Summary
Input: Phase 1 PK data (n=24), Phase 1b efficacy signals (n=12), preclinical GLP tox studies (28-day rat, 90-day dog), emerging QTc signal in 3 subjects.
Output:
Safety Summary – Section 2.3.5
Nonclinical Safety: 28-day rat study (GLP) at doses up to 100 mg/kg revealed no organ toxicity. 90-day dog study showed reversible hepatocyte hypertrophy at ≥50 mg/kg, not observed at 10 mg/kg. No genotoxicity in AMES or micronucleus.
Clinical Safety: 36 subjects across Phase 1/1b. Most common AE: headache (n=8, 22%), nausea (n=6, 17%), Grade 1-2. One Grade 2 QTc prolongation (475 ms) in subject receiving 400 mg; resolved upon dose reduction. No deaths, SAEs, or withdrawals due to safety.
Example 2: Annual Safety Update
Input: 12-month ongoing Phase 2b trial data (n=187), cumulative AE database, MedDRA coding, causality assessments.
Output:
Annual Safety Update – Year 1
AE Incidence: Overall AE rate 68% (127/187), consistent with year 1 baseline (69%). No new safety signals detected. GI AEs (n=34, 18%) remain most common, unchanged from pre-specified monitoring threshold. Serious AEs: 3 hospitalizations (pneumonia, appendicitis—unrelated; 1 Grade 3 drug-related rash).
Trend Analysis: QTc signal from IND phase resolved; mean QTc change from baseline –2 ms (95% CI: –8 to +4 ms).
What's Included
- SKILL.md instruction file: Complete toxicology report drafting workflow with regulatory templates
- IND Module 2.3 template: Pre-formatted sections for safety summary, detailed safety assessment, and laboratory summaries
- Annual Safety Update framework: Year-over-year trend analysis checklist with MedDRA coding guidelines
- Adverse Event synthesis checklist: Causality assessment, signal detection, and safety population definitions
- CTD compliance reference: Section numbering, regulatory language standards, and FDA/EMA formatting requirements
Who It's For
- Clinical toxicologists — Synthesizing safety data across preclinical and clinical programs
- Medical safety writers — Drafting regulatory-compliant safety narratives for submissions
- Regulatory affairs specialists — Assembling CTD modules and managing submission timelines
- Clinical development managers — Coordinating safety data for IND, ASR, and expedited reports
- Pharmacovigilance leads — Analyzing adverse event trends and preparing safety communications
Best For
- IND application safety modules — Initial comprehensive safety assessment for new drug investigations
- CTD Module 2.3 sections — Pre-approval dossier safety summaries and detailed assessments
- Annual Safety Update reports (ASR) — Year-over-year adverse event synthesis and trend analysis
- Expedited Safety Reports (ESR) — Rapid urgent safety communications for emerging signals
- Cross-trial safety meta-analysis — Clinical Development Safety Overviews for Phase transitions (2→3)
You might also like
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can submit raw mass spectrometry observations, instrument parameters, or sample preparation details to Claude and receive targeted diagnostic frameworks that explain anomalous results. Claude systematically generates plausible mechanistic explanations for unexpected protein abundance patterns, quantification inconsistencies, and PTM findings—then helps you design minimal, hypothesis-driven troubleshooting experiments to test them.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w